Numerous drugs are being developed and studied for the treatment of neurodegenerative diseases associated with the aberrant aggregation of tau protein, and the mechanisms of action of these drugs include the inhibition of aberrant post-translational modifications of tau protein, facilitation of the clearance and degradation of tau protein, and prevention of the aberrant aggregation of tau protein. This evidence concerns the gene MAPT and neurodegenerative disease.